Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $64000 | -$55M | 0.0% | -90740.6% | -$52M | — | $38M |
| 2024 | $26M | -$16M | 0.0% | -86.2% | -$24M | — | $78M |
| 2023 | $0 | -$62M | — | — | -$48M | — | $106M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $169000 | -$19M | 0.0% | -11601.8% | -$16M | — | $46M |
| Dec '25 | $0 | -$15M | — | — | -$11M | — | $38M |
| Sep '25 | $16000 | -$17M | 0.0% | -110481.3% | -$17M | — | $38M |
| Jun '25 | $48000 | -$13M | 0.0% | -27966.7% | -$13M | — | $41M |
| Mar '25 | $0 | -$10M | — | — | -$10M | — | $48M |
| Dec '24 | $698000 | -$9M | 0.0% | -1378.1% | -$3M | — | $78M |
| Sep '24 | $1M | -$13M | 0.0% | -1135.8% | -$13M | — | — |
| Jun '24 | $24M | $15M | 0.0% | 56.6% | -$8M | — | — |
| Mar '24 | — | -$9M | — | — | -$591000 | — | — |
How the market has priced CNTB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Connect Biopharma Holdings Ltd's multi-year trend.
As of FY2025, Connect Biopharma Holdings Ltd reported — of total debt against $38M of cash.
In FY2025, gross margin was —, operating margin -90740.6%, and net margin -86687.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.